NICE technology appraisals: Working with multiple levels of uncertainty and the potential for bias

Medicine, Health Care and Philosophy

Volumn 16, Issue 2, 2013, Pages 281-293

  Brown, Patrick ^a   Calnan, Michael ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Alzheimer's; Complexity; Hope; Polycentric regimes; Regulation; Uncertainty

Indexed keywords

EID: 84875997029     PISSN: 13867423     EISSN: 15728633     Source Type: Journal    
DOI: 10.1007/s11019-011-9376-2     Document Type: Article

References (54)

1. Abraham, J. 1995. Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation. London: UCL Press/Routledge.
2. Abraham, J. 2009. The pharmaceutical industry, the state and the NHS. In The new sociology of the health service, ed. J. Gabe, and M. Calnan. London: Routledge.
3. Alaszewski, A. 2002. The impact of the Bristol Royal Infirmary disaster and inquiry on public services in the UK. Journal of Interprofessional Care 16(4): 371-378.
4. Berger, P., and T. Luckmann. 1966. The social construction of reality. London: Penguin.
5. Black, J. 2008. Constructing and contesting legitimacy and accountability in polycentric regulatory regimes. Regulation & Governance 2: 137-164.
6. Brown, P. 2011. The dark side of hope and trust: Constructed expectations and the value-for-money regulation of new medicines. Health Sociology Review 20(4): 407-419.
7. Brown, N., and A. Webster. 2004. New medical technologies and society: Reordering life. Cambridge: Polity.
8. Brown, P., and M. Calnan. 2010. Political accountability of explicit rationing: Legitimacy problems faced by NICE. Journal of Health Services Research and Policy 15(2): 65-66.
9. Brubaker, R. 1984. The limits of rationality: An essay on the social and moral thought of Max Weber. London: Allen and Unwin.
10. Busfield, J. 2006. Pills, power, people: Sociological understandings of the pharmaceutical industry. Sociology 40(2): 297-314.
11. Calman, K., and D. Hine. 1995. A policy framework for commissioning cancer services: A report by the expert advisory group on cancer to the chief medical officers of England and Wales. London: Department of Health.
12. Crinson, I. 2004. The politics of regulation within the 'Modernized' NHS: the case of beta interferon and the 'Cost-Effective' treatment of multiple sclerosis. Critical Social Policy 24(1): 30-49.
13. Dyer, C. 2007. NICE's decision on dementia drugs was "irrational," High Court is told. BMJ 334: 1337.
14. Finucane, M., A. Alhakami, P. Slovic, and S. Johnson. 2000. The affect heuristic in judgments of risks and benefits. Journal of Behaviour Decision Making 13: 1-17.
15. Fuller, L. 1978. The forms and limits of adjudication. Harvard Law Review 92: 353-409.
16. Gigerenzer, G. 2007. Gut feelings. New York: Viking.
17. Habermas, J. 1976. Legitimation Crisis. Boston: Beacon.
18. Habermas, J. 1987. Theory of communicative action. Volume two: Lifeworld and system: a critique of functionalist reason. Cambridge: Polity.
19. Hedgecoe, A. 2004. The politics of personalised medicine: Pharmacogenetics in the clinic. Cambridge: Cambridge University Press.
20. Horton, R. 2004. The dawn of McScience. New York Review of Books 51(4): 7-9.
21. Ham, C., and K. Alberti. 2002. The medical profession, the public and the government. British Medical Journal 324: 838-842.
22. Harrison, S. 2009. Co-optation, commodification and the medical model: Governing UK medicine since1991. Public Administration 87(2): 184-197.
23. Kennedy, I. 2009. 'Kennedy report podcast' [Transcript]. http://www. nice. org. uk/newsroom/podcasts/index. jsp?pid=3&t=1 (accessed August 4, 2009).
24. Knight, F. 1921. Risk, uncertainty and profit. Boston: Houghton Mifflin.
25. Lam, A. 2000. Tacit knowledge, organizational learning and societal institutions: An integrated framework. Organization Studies 21: 487-513.
26. Langlois, R., and M. Cosgel. 1993. Frank knight on risk, uncertainty and the firm: A new interpretation. Economic Inquiry 31: 456-465.
27. Lehoux, P. 2006. The problem of health technology: Policy implications for modern healthcare systems. New York: Routledge.
28. Lehoux, P., J. L. Denis, M. Rock, M. Hivon, and S. Tailliez. 2009. How medical specialists appraise three controversial health innovations: Scientific, clinical and social arguments. Sociology of Health & Illness 32(1): 123-139.
29. Light, D., and D. Hughes. 2001. A sociological perspective on rationing: Power, rhetoric, and situated practices. Sociology of Health & Illness 23(5): 551-569.
30. Lindblom, C. 1959. The science of 'muddling through'. Public Administration Review 19: 79-88.
31. Lindblom, C. 1979. Still muddling, not yet through. Public Administration Review 39: 517-526.
32. Luhmann, N. 1979. Trust and Power. Chichester: Wiley.
33. Meadowcroft, J. 2008. Patients, politics, and power: Government failure and the politicization of UK. Health Care Journal of Medicine and Philosophy 33(5): 427-444.
34. Milewa, T. 2008. Representation and legitimacy in health policy formulation at a national level: Perspectives from a study of health technology eligibility procedures in the United Kingdom. Health Policy 85(3): 356-362.
35. Möllering, G. 2001a. The nature of trust: from Georg Simmel to a theory of expectation, interpretation and suspension. Sociology 35: 403-420.
36. Möllering, G. 2005. The Trust/control duality: An integrative perspective on positive expectations of others. International Sociology 20(3): 283-305.
37. Möllering, G. 2001b. The trust/control duality: An integrative perspective on positive expectations of others. International Sociology 20(3): 283-305.
38. Moran, M. 2003. The British regulatory state: High modernism and hyper innovation. Oxford: Oxford University Press.
39. Neuman, W. 2000. Social research methods: Qualitative and quantitative approaches. Boston: Allyn and Bacon.
40. NICE 2006. Final Appraisal Determination: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence. http://www. nice. org. uk/nicemedia/pdf/Final_FAD_with_updated_audit_advice_sent_to_C&Cs_250506. pdf. Accessed 4 August 2009.
41. NICE 2009. Report of threshold workshop. http://www. nice. org. uk/media/835/99/ITEM8ThresholdWorkshopReport. pdf. Accessed 4 August 2009.
42. Olson, M. 1965. The logic of collective action. Cambridge: Harvard University Press.
43. Power, M. 2005. The risk management of everything. London: Demos.
44. Schutz, A. 1972. The phenomenology of the social world. London: Heinemann.
45. Simon, H. 1982. Models of bounded rationality, volume 1: Economic analysis and public policy. Cambridge, Mass: MIT Press.
46. Smith, R. 2005. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med, 2(5): e138.
47. Sontag, S. 1978. Illness as metaphor. New York: Farrar, Straus & Giroux.
48. Taylor-Gooby, P. 2000. Risk and welfare. In Risk, trust and welfare, ed. P. Taylor-Gooby, 1-18. Basingstoke: Macmillan.
49. Thomas, A. 2004. Clinical assessment and investigations. In Cerebrovascular disease cognitive impairment and dementia, ed. J. O'Brien, D. Ames, L. Gustafson, M. Folstein, and E. Chiu. London: Martin Dunitz.
50. Wall Street Journal 2009. Of NICE and Men. July 7, 2011. http://online. wsj. com/article/SB124692973435303415. html. Accessed 20 August 2011.
51. Weber, M. 1968. Economy and Society, vol. 1. New York: Bedminster.
52. Wilkinson, D. 2004. Treatment of cognitive impairment in vascular dementia. In Cerebrovascular disease cognitive impairment and dementia, ed. J. O'Brien, D. Ames, L. Gustafson, M. Folstein, and E. Chiu. London: Martin Dunitz.
53. Williams, R. 2007. Tokens of trust. London: Canterbury Press.
54. Zinn, J. 2008. Heading into the unknown: everyday strategies for managing risk and uncertainty. Health, Risk and Society 10(5): 439-450.